About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Phase II Efficacy Study of AZD6244 in Colorectal Cancer

NCT00514761·3 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

colorectal cancer
require treatment but have failed one or two previous chemotherapeutic regimens that must have included oxaliplatin and/or irinotecan
have World Health Organisation (WHO) performance status 0-2 and life expectancy \> 12 weeks

You may not be if

previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine
any recent surgery, unhealed surgical incision or severe concomitant condition which makes it undesirable for the patient to participate in the study
nausea and vomiting, chronic gastrointestinal disease or significant bowel resection that would preclude adequate absorption

The record

StatusCompleted

PhasePhase 2

Taking part64

StartedSep 2006

UpdatedAug 13, 2014

Conditions

Metastatic Colorectal Cancer

Where3

Research Site
Goiânia, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil

Clareo Health | Phase II Efficacy Study of AZD6244 in Colorectal Cancer